Keywords: roche, xeloda, cleared, first-line, colorectal, cancer, therapy
Roche's Xeloda cleared as first-line colorectal cancer therapy in USA
Article | 02 May 2001
Roche's orally-active anticancer drug Xeloda (capecitabine) has beenapproved by the US Food and Drug Administration for the first-line treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
